BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 25,687 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $582,067.42. Following the completion of the transaction, the chief financial officer now owns 189,242 shares of the company's stock, valued at approximately $4,288,223.72. The trade was a 11.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Troy Wichterman also recently made the following trade(s):
- On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $103,775.00.
- On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total value of $16,803.60.
- On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.
- On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $26,668.74.
BioLife Solutions Stock Performance
NASDAQ:BLFS traded down $1.30 during trading hours on Tuesday, reaching $20.64. The company had a trading volume of 785,746 shares, compared to its average volume of 367,480. The firm has a market cap of $970.08 million, a price-to-earnings ratio of -19.47 and a beta of 1.93. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm's 50 day moving average price is $25.43 and its 200-day moving average price is $25.41. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. On average, analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.
Analysts Set New Price Targets
A number of research firms have weighed in on BLFS. Benchmark restated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright raised their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. StockNews.com raised BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Tuesday. KeyCorp lifted their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. Finally, Northland Securities boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.17.
View Our Latest Analysis on BioLife Solutions
Institutional Trading of BioLife Solutions
Several hedge funds have recently bought and sold shares of BLFS. Steward Partners Investment Advisory LLC bought a new position in shares of BioLife Solutions in the fourth quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BioLife Solutions during the 4th quarter worth approximately $31,000. 1620 Investment Advisors Inc. lifted its holdings in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 675 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after purchasing an additional 950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of BioLife Solutions in the fourth quarter worth approximately $171,000. Institutional investors own 93.24% of the company's stock.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Stories
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
